Information in the news releases is current on the date of the announcement, but is subject to change without prior notice.
-
December 24, 2021
LENVIMA® (lenvatinib) Plus KEYTRUDA® (pembrolizumab) Approved in Japan for Patients With Unresectable, Advanced or Recurrent Endometrial Carcinoma That Progressed After Cancer Chemotherapy
First Approval in Japan for the LENVIMA Plus KEYTRUDA Combination
-
December 24, 2021
INVESTIGATIONAL ALZHEIMER’S DISEASE THERAPY LECANEMAB GRANTED FDA FAST TRACK DESIGNATION
-
December 22, 2021
Japan’s First Committee on New Drugs of The Pharmaceutical Affairs and Food Sanitation Council Seeks Additional Data; Aducanumab Remains under Review
-
December 20, 2021
BIOGEN ANNOUNCES REDUCED PRICE FOR ADUHELM® TO IMPROVE ACCESS FOR PATIENTS WITH EARLY ALZHEIMER’S DISEASE IN THE UNITED STATES
-
December 20, 2021
EISAI ENTERS INTO COMMERCIALIZATION AND DISTRIBUTION AGREEMENT WITH GILEAD FOR JAK INHIBITOR FILGOTINIB IN ASIA
-
December 17, 2021
Update on Regulatory Submission for Aducanumab in the European Union
Biogen to seek re-examination following CHMP negative opinion for aducanumab
-
December 16, 2021
Update on the Phase 4 Confirmatory Study of ADUHELM®
-
December 6, 2021
EISAI TO PRESENT ABSTRACTS ON ONCOLOGY PRODUCTS AND PIPELINE AT 44TH ANNUAL SAN ANTONIO BREAST CANCER SYMPOSIUM
-
November 30, 2021
EISAI AND FCNT ENTER INTO BUSINESS ALLIANCE AIMING TO SUPPORT PEOPLE LIVING WITH DEMENTIA AND TO PREVENT DEMENTIA
Developing solutions such as smartphones equipped with the brain health check tool “NouKNOW®”
-
November 30, 2021
EISAI TO PRESENT LATEST DATA ON PERAMPANEL AND E2730 AT THE 75TH AMERICAN EPILEPSY SOCIETY ANNUAL MEETING
-
November 29, 2021
European Commission Approves LENVIMA® (lenvatinib) Plus KEYTRUDA® (pembrolizumab) for Patients With Certain Types of Endometrial Carcinoma
First Combination of Tyrosine Kinase Inhibitor with Immunotherapy Approved in Europe for Adult Patients With Advanced or Recurrent Endometrial Carcinoma With Disease Progression on or Following Prior Treatment With a Platinum-Containing Therapy in Any Setting and Who Are Not Candidates for Curative Surgery or Radiation
Approval Based on Study 309/KEYNOTE-775 Results Demonstrating Statistically Significant Improvements in Overall Survival and Progression-Free Survival Compared With Chemotherapy
-
November 29, 2021
European Commission Approves LENVIMA® (lenvatinib) Plus KEYTRUDA® (pembrolizumab) as First-Line Treatment for Adult Patients With Advanced Renal Cell Carcinoma
Approval Based on Results From CLEAR/KEYNOTE-581 Trial Demonstrating LENVIMA Plus KEYTRUDA Significantly Reduced the Risk of Disease Progression or Death by 61%, With a Median Progression-Free Survival of Nearly Two Years Versus Nine Months for Sunitinib
-
November 19, 2021
EISAI SELECTED FOR MEMBERSHIP IN DOW JONES SUSTAINABILITY ASIA PACIFIC INDEX 2021 FOR EIGHTH TIME
-
November 18, 2021
EISAI RECEIVES THE “MOST LIKED!” IR AWARD AT THE 2021 IR AWARD
-
November 17, 2021
Update on Regulatory Review of Aducanumab in the European Union
-
November 12, 2021
New Phase 3 Data Show Positive Correlation Between ADUHELM™ Treatment Effect on Biomarkers and Reduction in Clinical Decline in Alzheimer’s Disease
-
November 12, 2021
EISAI PRESENTS NEW ANALYSIS OF LECANEMAB CLINICAL EFFICACY RESULTS FROM PHASE 2B STUDY AT CLINICAL TRIALS ON ALZHEIMER’S DISEASE (CTAD) CONFERENCE
Consistency of Efficacy Assessments Evaluated Across Various Statistical Methods
-
November 12, 2021
INTRODUCTION OF FIRST-OF-A-KIND PLASMA-BASED BIOMARKER SCREENING TO FACILITATE IDENTIFICATION OF SUBJECTS FOR PHASE 3 AHEAD 3-45 TRIAL PRESENTED AT CLINICAL TRIALS ON ALZHEIMER’S DISEASE (CTAD) CONFERENCE
-
November 11, 2021
EISAI PRESENTS LATE-BREAKER UPDATES ON LECANEMAB CLINICAL, BIOMARKER AND SAFETY DATA FROM PHASE 2B STUDY CORE AND OPEN-LABEL EXTENSION ACROSS FIVE YEARS AT CLINICAL TRIALS ON ALZHEIMER’S DISEASE (CTAD) CONFERENCE
-
November 9, 2021
DIAN-TU SELECTS LECANEMAB AS BACKGROUND ANTI-AMYLOID THERAPY IN CLINICAL TRIAL EVALUATING INVESTIGATIONAL THERAPY TARGETING TAU FOR DOMINANTLY INHERITED ALZHEIMER'S DISEASE
Eisai’s anti-microtubule binding region (MTBR) tau antibody E2814 previously selected as the first investigational therapy among anti-tau drugs for the DIAN-TU Tau Next Generation trial
-
November 4, 2021
Eisai and Digital Garage, Inc. Jointly Launch “Onlab Bio Dementia (Open Network Lab BioHealth Dementia Innovation Challenge)”, a Collaborative Cultivation Program with Dementia-related Startups
-
November 4, 2021
EISAI PRESENTS NEW DATA ON THE RELATIONSHIP BETWEEN CLINICAL, BIOMARKER AND SAFETY OUTCOMES FROM THE LECANEMAB PHASE 2B STUDY FOR EARLY ALZHEIMER’S DISEASE IN LATE-BREAKERS AND PIPELINE UPDATES AT THE 14TH CLINICAL TRIALS ON ALZHEIMER’S DISEASE (CTAD) CONFERENCE
-
November 1, 2021
The CREB-binding protein (CBP)/β-catenin inhibitor E7386, co-created by Eisai and PRISM BioLab, achieved the clinical POC (Proof of Concept)
-
October 18, 2021
Eisai and Merck & Co., Inc., Kenilworth, N.J., U.S.A. Receive Positive EU CHMP Opinions for LENVIMA® (lenvatinib) Plus KEYTRUDA® (pembrolizumab) in Two Different Types of Cancer
Positive Opinion Granted for Advanced Renal Cell Carcinoma Based on Significant Progression-Free Survival (PFS), Overall Survival (OS) and Objective Response Rate (ORR) Benefit Compared to Sunitinib in CLEAR/KEYNOTE-581 Trial
Positive Opinion Granted for Advanced Endometrial Carcinoma Based on Significant OS and PFS Benefit Compared to Chemotherapy in Study 309/KEYNOTE-775 Trial
-
September 28, 2021
EISAI INITIATES ROLLING SUBMISSION TO THE U.S. FDA FOR BIOLOGICS LICENSE APPLICATION OF LECANEMAB (BAN2401) FOR EARLY ALZHEIMER’S DISEASE UNDER THE ACCELERATED APPROVAL PATHWAY
LECANEMAB IS AN ANTI-AMYLOID BETA (Aβ) PROTOFIBRIL ANTIBODY
-
September 27, 2021
Fully Human Anti-TNFα Monoclonal Antibody HUMIRA® Obtains Additional Approval for High-Dose Regimen of Ulcerative Colitis in Adult Patients and for New Regimen in Pediatric Patients
-
September 14, 2021
EISAI TO JOIN THE GLOBAL ENVIRONMENTAL INITIATIVE “RE100”
-
September 14, 2021
EISAI TO PRESENT ABSTRACTS ON ONCOLOGY PRODUCTS AND PIPELINE AT ESMO VIRTUAL CONGRESS 2021
-
September 13, 2021
AbbVie, Eisai, and EA Pharma Launch “Humira® Support Tool Ordering Service for Patients” - an Initiative to Improve Patients’ Adherence to Humira® Therapy -
-
August 31, 2021
Eisai and FUJI YAKUHIN Conclude License Agreement Concerning the Development and Distribution of Dotinurad, a Treatment for Hyperuricemia and Gout, in Five ASEAN Countries
-
August 16, 2021
ANTICANCER AGENT “TAZVERIK® TABLETS 200mg” (TAZEMETOSTAT HYDROBROMIDE) LAUNCHED IN JAPAN FOR EZH2 GENE MUTATION-POSITIVE FOLLICULAR LYMPHOMA
-
August 12, 2021
FDA Approves LENVIMA® (lenvatinib) Plus KEYTRUDA® (pembrolizumab) Combination for First-Line Treatment of Adult Patients With Advanced Renal Cell Carcinoma (RCC)
LENVIMA Plus KEYTRUDA Is Now Approved for Two Types of Cancer, Including Advanced RCC
Based on Phase 3 CLEAR/KEYNOTE-581 Trial, LENVIMA Plus KEYTRUDA Significantly Reduced Risk of Disease Progression or Death by 61% Versus Sunitinib
-
August 5, 2021
EISAI RECEIVES AWARD FOR EXCELLENCE IN CORPORATE COMMUNICATIONS AT THE 37TH CORPORATE COMMUNICATIONS AWARDS
-
August 4, 2021
Notification Regarding Revision of Consolidated Financial Forecasts (IFRS) for the Fiscal Year Ending March 31, 2022
-
August 2, 2021
ANTI-EPILEPTIC DRUG FYCOMPA® APPROVED IN CHINA AS MONOTHERAPY FOR PARTIAL-ONSET SEIZURES AND PEDIATRIC INDICATION FOR PARTIAL-ONSET SEIZURES
-
July 30, 2021
LATE-BREAKING AAIC PRESENTATION EXPLORES POTENTIAL CLINICAL EFFECTS OF LECANEMAB (BAN2401)
Eisai and Biogen Present Preliminary Assessment of the Clinical Effects of Lecanemab Following 18 Months of Treatment in the Open Label Extension of the Phase 2 Proof of Concept Study at 2021 Alzheimer’s Association International Conference (AAIC)
-
July 30, 2021
Biogen and Eisai Announce Design of ADUHELM ICARE AD-US Study, the First Real-World Observational Phase 4 Study in Alzheimer’s Disease at AAIC 2021
-
July 29, 2021
EISAI LISTED FOR 20TH CONSECUTIVE YEAR IN FTSE4GOOD INDEX SERIES, AN INDEX FOR SOCIALLY RESPONSIBLE INVESTMENT
-
July 27, 2021
Biogen and Eisai Announce ADUHELM™ (aducanumab-avwa) Data Presentations at Alzheimer’s Association International Conference 2021
-
July 22, 2021
FDA Approves LENVIMA® (lenvatinib) Plus KEYTRUDA® (pembrolizumab) Combination for Patients With Certain Types of Advanced Endometrial Carcinoma
Immunotherapy and Tyrosine Kinase Inhibitor Combination Approved for the Treatment of Patients With Advanced Endometrial Carcinoma That is Not Microsatellite Instability-High or Mismatch Repair Deficient, Who Have Disease Progression Following Prior Systemic Therapy in Any Setting and Are Not Candidates for Curative Surgery or Radiation
Study Results Demonstrated Statistically Significant Improvements in Overall Survival, Progression-Free Survival and Overall Response Rate, Helping to Address a Significant Unmet Need in Advanced Endometrial Carcinoma
-
July 21, 2021
EISAI TO PRESENT LATEST DATA ON PIPELINE ASSETS IN THE AREA OF ALZHEIMER’S DISEASE AND DEMENTIA AT THE ALZHEIMER’S ASSOCIATION INTERNATIONAL CONFERENCE (AAIC) 2021
-
July 19, 2021
EISAI LAUNCHES BILE ACID TRANSPORTER INHIBITOR GOOFICE® IN THAILAND
-
July 19, 2021
STATUS OF ADUHELM™ IN THE UNITED STATES
-
July 8, 2021
FDA Approves Updated ADUHELM™ Prescribing Information to Emphasize Population Studied in Clinical Trials
ADUHELM should be initiated in patients with mild cognitive impairment due to Alzheimer’s disease or mild Alzheimer’s dementia
-
June 30, 2021
EISAI LAUNCHES IN-HOUSE DEVELOPED ANTI-INSOMNIA DRUG DAYVIGO® (LEMBOREXANT) IN HONG KONG
FIRST LAUNCH FOR DAYVIGO IN ASIA OUTSIDE OF JAPAN
-
June 29, 2021
Position and Policy Regarding Reduction in the Trading Unit of the Company's Shares
-
June 24, 2021
EISAI AND BIOGEN INC. ANNOUNCE U.S. FDA GRANTS BREAKTHROUGH THERAPY DESIGNATION FOR LECANEMAB (BAN2401), AN ANTI-AMYLOID BETA PROTOFIBRIL ANTIBODY FOR THE TREATMENT OF ALZHEIMER’S DISEASE
-
June 23, 2021
SHELF REGISTRATION FOR ISSUANCE OF STOCK OPTIONS
-
June 23, 2021
ANTICANCER AGENT “TAZVERIK® TABLETS 200mg” (TAZEMETOSTAT HYDROBROMIDE) APPROVED IN JAPAN FOR EZH2 GENE MUTATION-POSITIVE FOLLICULAR LYMPHOMA
-
June 18, 2021
CONTINUATION OF “POLICY FOR PROTECTION OF THE COMPANY’S CORPORATE VALUE AND COMMON INTERESTS OF SHAREHOLDERS (SHAREHOLDER RIGHTS PLAN)”
-
June 18, 2021
EISAI AND BRISTOL MYERS SQUIBB ENTER INTO GLOBAL STRATEGIC COLLABORATION FOR EISAI’S MORAb-202 ANTIBODY DRUG CONJUGATE
-
June 15, 2021
EISAI TO DIVEST RIGHTS FOR ZONEGRAN® IN EUROPE AND OTHER REGIONS TO ADVANZ PHARMA
-
June 9, 2021
EISAI RECEIVES SPECIAL PRIZE AT PLATINUM CAREER AWARD 2021
-
June 9, 2021
EISAI TO PRESENT LATEST DATA OF LEMBOREXANT AT 35th ANNUAL SLEEP MEETING (SLEEP2021)
-
June 8, 2021
Biogen and Eisai launch initiatives to help patients with Alzheimer’s disease access ADUHELM™
-
June 8, 2021
FDA grants accelerated approval for ADUHELM™ as the first and only Alzheimer’s disease treatment to address a defining pathology of the disease
The accumulation of amyloid beta plaques in the brain is a defining pathology of Alzheimer’s disease
In clinical trials, ADUHELM reduced amyloid beta plaques by 59 to 71 percent at 18 months of treatment
-
June 7, 2021
New Data on LENVIMA® (lenvatinib) Plus KEYTRUDA® (pembrolizumab) Versus Sunitinib in First-Line Treatment for Patients With Advanced Renal Cell Carcinoma From Pivotal Phase 3 CLEAR/KEYNOTE-581 Trial Presented at 2021 ASCO Annual Meeting
Results From New Analysis Evaluating Health-Related Quality of Life (HRQoL) Based on Patient-Reported Outcomes Using Three HRQoL Scales
-
May 31, 2021
Eisai and ITO EN Enter Into Business Alliance Aiming to Support People Living with Dementia and to Prevent Dementia
-
May 20, 2021
EISAI TO PRESENT DATA ON ONCOLOGY PIPELINE AND PRODUCTS AT ASCO ANNUAL MEETING
-
May 19, 2021
ANTICANCER AGENT “Remitoro® INTRAVENOUS DRIP INFUSION 300μg” (DENILEUKIN DIFTITOX (GENETICAL RECOMBINATION)) LAUNCHED IN JAPAN FOR PERIPHERAL T-CELL LYMPHOMA AND CUTANEOUS T-CELL LYMPHOMA
-
May 14, 2021
EISAI AND NATIONAL CANCER CENTER COMMENCE JOINT RESEARCH AND DEVELOPMENT PROJECT “BASIC RESEARCH ON THE DRUG DISCOVERY AND DEVELOPMENT TO ACCELERATE DEVELOPMENT OF ANTICANCER DRUGS IN TREATMENT OF PATIENTS WITH RARE CANCERS AND REFRACTORY CANCERS”, USING PDX WITH HIGH PREDICTABILITY OF CLINICAL OUTCOMES, AND CANCER GENOME DATA
-
May 11, 2021
EISAI'S STATEMENT OF COMMITMENT FOR CARBON NEUTRALITY BY 2040
A medium- to long-term goals to achieve carbon neutrality
-
May 6, 2021
Eisai and Merck & Co., Inc., Kenilworth, N.J., U.S.A. Receive Priority Review From FDA for LENVIMA® (lenvatinib) Plus KEYTRUDA® (pembrolizumab) Applications for Advanced Renal Cell Carcinoma and for Advanced Endometrial Carcinoma
Applications Based on Progression-Free Survival, Overall Survival, and Objective Response Rate Data From Respective Pivotal Phase 3 Trials
-
April 28, 2021
RESONA and Eisai Enter Into Business Alliance Aiming to Support People Living with Dementia and to Prevent Dementia in Saitama Prefecture, Japan
Building Dementia Ecosystem
-
April 23, 2021
APPLICATION SUBMITTED FOR ADDITIONAL INDICATION OF ANTI CANCER AGENT LENVIMA® IN COMBINATION WITH KEYTRUDA® AS A TREATMENT FOR ADVANCED UTERINE BODY CANCER IN JAPAN
-
April 23, 2021
GILEAD SCIENCES SUBMITS NEW DRUG APPLICATION IN JAPAN FOR FILGOTINIB FOR THE TREATMENT OF ULCERATIVE COLITIS WITH AN INADEQUATE RESPONSE TO CONVENTIONAL THERAPIES
Application is Based on Phase 2b/3 SELECTION Study Data with Patients with Moderately to Severely Active Ulcerative Colitis
-
April 23, 2021
NOTICE REGARDING BIOGEN’S DISCLOSURE ABOUT THE SUBMISSION OF MARKETING AUTHORIZATION APPLICATIONS IN BRAZIL, CANADA, AUSTRALIA, AND SWITZERLAND FOR ADUCANUMAB FOR ALZHEIMER’S DISEASE
-
April 20, 2021
18-Month, Pre-Specified Analysis Showing Consistent Reduction in Clinical Outcome Measures from a Lecanemab (BAN2401) Phase 2b Clinical Trial in Early Alzheimer’s Disease Published in Peer-Reviewed Journal, Alzheimer’s Research and Therapy
Lecanemab Phase 3 Clarity AD Clinical Trial Completed Enrollment
-
April 14, 2021
EISAI TO PRESENT LATEST DATA ON NEUROLOGY PRODUCTS AND PIPELINES AT THE AMERICAN ACADEMY OF NEUROLOGY ANNUAL MEETING
-
April 12, 2021
AN ANIMATION FEATURING LYMPHATIC FILARIASIS ELIMINATION ACTIVITIES RECEIVES ANIMATION AWARD AT INTERNATIONAL SOCIETY FOR NEGLECTED TROPICAL DISEASES FESTIVAL 2021
-
March 31, 2021
KYORIN and Eisai Enter Into License Agreement Concerning the Development and Marketing of Vibegron, a Treatment for Overactive Bladder, in Four ASEAN Countries
-
March 31, 2021
APPLICATION SUBMITTED FOR ADDITIONAL INDICATION OF ANTI CANCER AGENT LENVIMA® IN COMBINATION WITH KEYTRUDA® AS A TREATMENT FOR ADVANCED RENAL CELL CARCINOMA IN JAPAN
-
March 30, 2021
EUROPEAN MEDICINES AGENCY ACCEPTS THE MARKETING AUTHORISATION APPLICATIONS FOR TWO ADDITIONAL INDICATIONS OF ANTI CANCER AGENT LENVATINIB IN COMBINATION WITH PEMBROLIZUMAB AS A TREATMENT FOR ADVANCED RENAL CELL CARCINOMA AND ADVANCED ENDOMETRIAL CARCINOMA
-
March 26, 2021
DISCOVERY RESEARCH ON AMPA-TYPE GLUTAMATE RECEPTOR ANTAGONIST PERAMPANEL HONORED WITH PSJ AWARD FOR DRUG RESEARCH AND DEVELOPMENT 2021
-
March 23, 2021
LENVIMA®（LENVATINIB） APPROVED FOR ADDITIONAL INDICATION OF UNRESECTABLE THYMIC CARCINOMA IN JAPAN
-
March 23, 2021
ANTICANCER AGENT “Remitoro® INTRAVENOUS DRIP INFUSION 300μg”(DENILEUKIN DIFTITOX (GENETIC RECOMBINANT)) APPROVED IN JAPAN FOR PERIPHERAL T-CELL LYMPHOMA AND CUTANEOUS T-CELL LYMPHOMA
-
March 22, 2021
EISAI BEGINS CONSTRUCTION OF ITS NEW INJECTION/RESEARCH BUILDING AT KAWASHIMA INDUSTRIAL PARK IN JAPAN
-
March 22, 2021
EISAI AWARDED THE NEW DIVERSITY MANAGEMENT SELECTION 100
-
March 19, 2021
LENVIMA® (lenvatinib) Plus KEYTRUDA® (pembrolizumab) Significantly Improved Progression-Free Survival and Overall Survival Versus Chemotherapy in Patients With Advanced Endometrial Cancer Following Prior Platinum-Based Chemotherapy in Phase 3 Study
LENVIMA Plus KEYTRUDA Significantly Reduced the Risk of Death by 38%, With a Median Overall Survival of 18.3 Months Versus 11.4 Months With Chemotherapy Regardless of Mismatch Repair Status
First Results From Pivotal Study 309/KEYNOTE-775 Trial Presented at Society of Gynecologic Oncology (SGO) 2021 Annual Meeting on Women’s Cancer
-
March 17, 2021
DZNE and EISAI ENTER INTO RESEARCH COLLABORATION AGREEMENT AIMING FOR NOVEL DRUG DISCOVERY FOR NEURODEGENERATIVE DISORDERS
-
March 16, 2021
ANTI-MTBR (MICROTUBULE BINDING REGION) TAU ANTIBODY E2814 IS SELECTED ON CLINICAL STUDY FOR DOMINANTLY INHERITED ALZHEIMER'S DISEASE BY DIAN-TU
-
March 12, 2021
MINISTRY OF HEALTH, LABOUR AND WELFARE GRANTS ORPHAN DRUG DESIGNATION IN JAPAN TO ANTI-CANCER AGENT LENVIMA® (LENVATINIB) WITH PROSPECTIVE INDICATION FOR UTERINE BODY CANCER
-
March 5, 2021
EISAI TO PRESENT LATEST DATA ON PIPELINE ASSETS IN THE AREA OF ALZHEIMER’S DISEASE AND DEMENTIA AT THE 15TH INTERNATIONAL CONFERENCE ON ALZHEIMER’S AND PARKINSON’S DISEASE
-
March 4, 2021
EISAI CERTIFIED IN 2021 AS OUTSTANDING HEALTH AND PRODUCTIVITY MANAGEMENT ORGANIZATION (WHITE 500)
-
March 4, 2021
EISAI TO SUPPORT CONSTRUCTION OF SCREENING FRAMEWORK FOR THE NOVEL CORONAVIRUS INFECTION IN KENYA
-
March 2, 2021
NEW DRUG APPROVAL FOR IN-HOUSE DEVELOPED ANTI-INSOMNIA DRUG DAYVIGO® (LEMBOREXANT) IN HONG KONG
FIRST DRUG APPROVAL FOR DAYVIGO IN ASIA OUTSIDE OF JAPAN
-
February 22, 2021
MHLW GRANTS ORPHAN DRUG DESIGNATION IN JAPAN TO NOVEL FIBROBLAST GROWTH FACTOR (FGF) RECEPTOR SELECTIVE TYROSINE KINASE INHIBITOR E7090 WITH PROSPECTIVE INDICATION FOR UNRESECTABLE BILIARY TRACT CANCER WITH FGFR2 GENE FUSION
-
February 22, 2021
EISAI RECEIVES CORPORATE PHILANTHROPY AWARD FOR ITS EFFORTS TO REALIZE human health care (hhc) PHILOSOPHY
-
February 15, 2021
LENVIMA® (lenvatinib) Plus KEYTRUDA® (pembrolizumab) Demonstrated Superior Progression-Free Survival (PFS) and Overall Survival (OS) Versus Sunitinib as First-Line Treatment for Patients With Advanced Renal Cell Carcinoma
LENVIMA Plus KEYTRUDA Significantly Reduced Risk of Disease Progression or Death by 61% Versus Sunitinib, With a Median PFS of Nearly Two Years Versus Nine Months for Sunitinib
LENVIMA Plus Everolimus Significantly Improved PFS and Objective Response Rate Versus Sunitinib
First Results From Pivotal CLEAR Study (Study 307/KEYNOTE-581) Presented at 2021 Genitourinary Cancers Symposium (ASCO GU) and Published in the New England Journal of Medicine
-
February 3, 2021
Notification Regarding Revision of Consolidated Financial Forecasts (IFRS) for the Fiscal Year Ending March 31, 2021
-
February 1, 2021
EISAI TO LAUNCH PARKINSON’S DISEASE TREATMENT EQUFINA® IN SOUTH KOREA
-
January 29, 2021
Biogen and Eisai Announce FDA’s 3-Month Extension of Review Period for the Biologics License Application for Aducanumab
The new Prescription Drug User Fee Act (PDUFA) action date set by the FDA is June 7, 2021
-
January 25, 2021
EISAI LISTED AS A GLOBAL 100 MOST SUSTAINABLE CORPORATION FOR THE FIFTH TIME
HIGHEST RANKED GLOBAL PHARMACEUTICAL COMPANY
-
January 12, 2021
EISAI TO PRESENT ABSTRACTS ON LENVATINIB AT 2021 GASTROINTESTINAL CANCERS SYMPOSIUM
